1	COVID-19 serological survey using micro blood sampling
2	
2	Malian M. Matthews <sup>1†</sup> Tao Cuur Kim <sup>1†</sup> Catachi Chihata <sup>1†</sup> Marila Chihata <sup>1</sup> Christian
3	Nielissa M. Matthews <sup>1</sup> , Tae Gyun Kim <sup>1</sup> , Satoshi Shibata <sup>1</sup> , Noriko Shibata <sup>2</sup> , Christian
4 F	Butcher-, Jaekyung Hyun-, Keon Young Kim-, Theodore Robb-, Slang Sheng Jheng-, Masashi
Э	Narita', Tomoari Mori', Mary Comins' & Matthias Woll''
6	<sup>1</sup> Molecular Cryo-Electron Microscopy Unit, Okinawa Institute of Science and Technology
7	Graduate University (OIST), Onna-son, Okinawa, Japan.
8	<sup>2</sup> Fluid Mechanics Unit, OIST, Onna-son, Okinawa, Japan.
9	<sup>3</sup> IT Division, Infrastructure Section, OIST, Onna-son, Okinawa, Japan.
10	<sup>4</sup> Okinawa Chubu Hospital, Division of Infectious Diseases, Okinawa City, Okinawa, Japan
11	<sup>5</sup> Research Support Division, Occupational Health and Safety, OIST, Onna-son, Okinawa,
12	Japan.
13	<sup>6</sup> Research Support Division, Office of the Provost, OIST, Onna-son, Okinawa, Japan.
14	<sup>+</sup> these authors have contributed equally
15	*Correspondence to matthias.wolf@oist.jp
16	
17	Abstract
18	
19	During August 2020, we carried out a serological survey among students and employees at
20	the Okinawa Institute of Science and Technology Graduate University (OIST), Japan, testing
21	for the presence of antibodies against SARS-CoV-2, the causative agent of COVID-19. We used
22	a FDA-authorized 2-step ELISA protocol (1, 2) in combination with at-home self-collection of
23	blood samples using a custom low-cost finger prick-based capillary blood collection kit.
24	Although our survey did not find any COVID-19 seropositive individuals among the OIST
25	cohort, it reliably detected all positive control samples obtained from a local hospital and
26	excluded all negatives controls. We found that high serum antibody titers can persist for at
27	least up to 6.5 months post infection. Among our controls, we found strong cross-reactivity
28	of antibodies in samples from a serum pool from two MERS patients in the anti-SARS-CoV-2-
29	ኇፚዀጟጟዀዀዀዀዀዀዀዀዀዀዀዀዀዀዀዀዀዀዀዀዀዀዀዀዀዀዀዀዀዀዀዀዀዀ

30 blood collection using as little as one drop of blood can reliably assess the seroprevalence 31 among communities. Anonymous sample tracking and an integrated website created a 32 stream-lined procedure. Major parts of the workflow were automated on a liquid handler, 33 demonstrating scalability. We anticipate this concept to serve as a prototype for reliable 34 serological testing among larger populations.

35

### 36 Background and Introduction

37

38 At the beginning of 2020, COVID-19 emerged from Hubei province in southern China and 39 quickly spread across the globe. Due to its proximity and direct flight connections between 40 the epicenter in Wuhan and its capital Tokyo, the Japanese Nation was among the first to 41 experience cases of the disease outside China, documenting its first case on January 15, 2020. 42 In early April, as the tourism season in Okinawa began to ramp up, so did the new cases of 43 COVID-19 in Okinawa. A first wave of COVID-19 cases peaked at the moderate rate of 10 44 cases/day in mid-April (total number 132 cases), which was effectively reduced by 5 weeks of 45 lock-down measures to no additional cases within the next two months. From early August 46 on, however, a second, much stronger wave of infections has, at the time of this report, 47 culminated in more than 2,682 accumulated cases on the island (October 8, 2020). The 48 present study was conducted at the beginning of this second wave.

49

50 Serological surveys which detect the presence of antibodies against SARS-CoV-2 antigens can provide important information to the government for issuing health care 51 52 guidelines. At the beginning of April 2020, we obtained plasmids for coronavirus surface 53 antigens from the Krammer Lab at the Icahn School of Medicine (NY, NY, USA). We established 54 protein expression and purification in a mammalian cell line and set up an ELISA following the 55 2-step assay developed by the same group (1). Their assay has received emergency use 56 authorization by the U.S. Food & Drug Administration (FDA) (2). We secured PCR-confirmed 57 human sera from COVID-19 positive patients at the local hospital as well as negative controls 58 from serum collected before December 2019. Once the assay itself was validated, we set up 59 partially automated sample handling on a robotic liquid handler, established a website with 60 a barcoding system for anonymous sample tracking, and conducted a serological survey of 61 staff and students at our institution.

62 In emergency situations such as during COVID-19, the health care system is under stress; it cannot be expected that trained clinical personnel are available to draw patient 63 64 blood by venous puncture. Furthermore, non-essential human traffic in hospitals and other 65 health care institutions should ideally be limited to protect vital health care workers from risk 66 of exposure to potential carriers of the virus. To overcome this limitation, we distributed easy-67 to-use, self-administered micro blood sampling kits to participants. The kit uses a single-use 68 safety lancet to collect a few drops of capillary blood from the participant's finger. We show that antibody titers obtained by micro blood sampling are equivalent to serum antibody titers 69 70 from blood drawn by conventional venous puncture. This low-cost, easily deployable self-71 sampling method in combination with a highly sensitive and specific ELISA in a centralized 72 testing lab provides a scalable solution that can enable serological surveys of larger 73 populations.

74

#### 75 Methods

76

### 77 Protein Expression and Purification

78 Plasmids for mammalian expression of the SARS-CoV-2 S (spike) protein receptor-binding 79 domain (RBD, residues 319-541) and stabilized His-tagged SARS-CoV-2 S including a T4 foldon 80 trimerization tag were generously provided by Florian Krammer and colleagues at the Icahn 81 School of Medicine (NY, NY, USA) (3). Proteins were expressed in Expi293F cells and purified 82 by Ni-NTA affinity and size-exclusion chromatography as described previously (1). The yield was 15 mg/L and 4 mg/L for RBD and the trimeric SARS-CoV-2 S, respectively. 500 µL aliquots 83 of purified protein at a concentration of 10 µg/mL were frozen in liquid nitrogen and stored 84 85 at -80 °C until use. We expressed and purified both the S∆cs (furin cleavage site deletion RRAR to A) and S∆cspp construct (cleavage site deletion and stabilizing mutations K986P and V987P) 86 87 (3), but only the S $\Delta$ cs protein was used in this study. Protein purity was verified by SDS-PAGE 88 and confirmed by Western blot with MonoRab<sup>™</sup> Anti-His Tag (C-term) Antibody (Nr. 25B6E11, 89 GenScript, USA).

90

### 91 *Electron microscopy*

92 The quality and folding of two proteins, the RBD and SARS-CoV-2 S, were verified by93 biochemical methods and correct folding and assembly of the trimeric spike protein was

confirmed using cryo-electron microscopy (Figure 1). Sample solution was applied to a carbon
coated copper grid and stained with 1 % uranyl acetate. The protein particles were visualized
with a Talos L120 transmission electron microscope (Thermo Fisher Scientific, USA) operating
at 120 kV acceleration voltage.

For cryo-EM, 3 µL of purified trimeric spike sample solution was applied to UltrAuFoil 98 R1.2/1.3 grids pre-treated with a Solarus advanced plasma system (Model 950, Gatan, USA) 99 100 for 60 seconds at 25 °C in a 23 % H<sub>2</sub>, 77 % O<sub>2</sub> gas mix. The grids were blotted and vitrified in a 101 Vitrobot Mark IV (Thermo Fisher Scientific, USA) using a liquid ethane-propane mixture. Cryo-102 EM grids and particle density were optimized by screening based on protein concentration in 103 the range of 2-3 mg/mL. Particles Images of trimeric spike protein in amorphous ice were 104 collected with a Titan Krios transmission electron microscope (Thermo Fisher Scientific, US) 105 operating at 300 kV on a Falcon-3EC camera (Thermo Fisher Scientific, US) in counting mode, at a pixel size of 1.08 Å (at the specimen level). Frames from 1,479 movies were aligned, dose-106 107 weighted and summed using motioncor2 (4). Contrast transfer function (CTF) estimation, 108 particle picking and 2D classification were performed with RELION 3.1 (5). A total of 1,119,504 109 particles were picked semi-automatically, of which 297,144 particles were retained after 2D 110 classification.

111

### 112 Sample collection and heat inactivation

113 The micro blood sampling kits were assembled in 8x12 cm sealable plastic bags, including BD Microtainer<sup>®</sup> contact-activated lancet (Becton Dickison, NJ, USA), blood collection tube 114 containing a coagulant and a separator gel (Greiner Bio-one MiniCollect<sup>®</sup> TUBE 0.5/0.8 CAT 115 116 Serum Separation Clot Activator gold cap), packaged alcohol wipes, adhesive bandage, and 117 peelable sticker with a linear tube barcode (Code 128) and a matching QR code encoding a 118 link to our website. After finger prick with the safety lancet, users collected 1-5 drops (approx. 30-150 µL) of capillary blood into the serum separation tube and attached the linear barcode. 119 Serum separation tubes were centrifuged at 5,000  $\times$  g for 5 min at 4  $^{\circ}$ C under biosafety level 120 2 (BSL2) conditions, then inactivated in a water bath at 56 °C for 1 hr. Heat-inactivated 121 samples were stored at 4 °C until use for ELISA. After scanning tube barcodes for each plate 122

All rights reserved. No reuse allowed without permission.

into a CSV file with a hand-held scanner, separated serum was transferred into barcoded 96-well plates using manual pipetting.

125

#### 126 ELISA and automation

We followed the 2-step ELISA protocol developed by the Krammer lab (1). ELISA plate formats were modified as depicted in Supplementary Figure 1C. Modified plate designs included two dilution series of positive control, which provided an internal standard. Additional negative controls were included to provide a cutoff that was consistently within the suggested range of 0.15-0.2 AU (Absorbance Units) at 492 nm.

132 We implemented a partially automated workflow on a Beckman Biomek FX<sup>P</sup> (Beckman 133 Coulter, Indianapolis, IN, USA) liquid handling robot for two steps of the ELISA protocol, namely, for (i) dilution and transfer of serum samples for RBD screening plates and for (ii) 134 135 plate developing and reading of all plates. Plates were stacked to maximize throughput and usage of available deck space. Automated dilution and transfer of serum samples utilized a 136 137 96-well plate containing 5X diluted serum in PBS, termed the D1 (dilution 1) plate as a source plate. Sample from the D1 plate was diluted with a PBS-T milk solution in a second 96-well 138 139 plate, termed the D2 (dilution 2) plate, and finally transferred to the destination ELISA plate 140 according to the published protocol (1). After dilution, D1 plates were immediately wrapped in parafilm and stored at 4 °C. If a given sample tested positive against RBD antigen in step 1, 141 142 a fresh 5x diluted sample was prepared using solution remaining in the serum separation 143 tubes. If the volume of the remaining serum was insufficient, the 5x diluted sample from the 144 D1 plate was used for the confirmatory step 2.

For automated plate development and reading, 100  $\mu$ L of Sigma*Fast*<sup>TM</sup> OPD 145 146 development solution (Sigma Aldrich) was prepared according to the described protocol and 147 added to all wells. A wait time was programmed in the liquid handler workflow so that exactly 148 10 minutes after addition of OPD, 50  $\mu$ L of 3 M HCl were added to quench the reaction. 149 Immediately after addition of HCl to a given plate, the plate was automatically loaded into 150 and read on a DTX800 multimode plate reader (Beckman Coulter, Indianapolis, IN, USA) at 492 nm wavelength. Functions were added within the automation code to automatically 151 calculate threshold values for each plate and output a "positive" or "negative" result for each 152

153 sample. All other steps, including washing on an AquaMax 4000 plate washer (Molecular
154 Devices LLC, San Jose, CA, USA), were carried out manually.

155

### 156 Controls and Standards

Three positive controls in the form of intravenous blood sera from confirmed SARS-CoV-2 157 PCR-positive patients (collected 10-30 days post onset of symptoms) were obtained from 158 159 Naha Municipal Hospital, Naha, Japan. After titer analysis of all three samples (data not shown), the two samples with the strongest titers were pooled and used as the positive 160 161 control for all assays. Positive controls (collected at least 90 days after onset of symptoms) 162 for validation of the capillary blood collection method were obtained from Okinawa Chubu 163 Hospital, Uruma City, Japan. Negative controls taken from patients prior to November 2019 164 were obtained from Naha Municipal Hospital from intravenous blood, and from a commercial 165 serum pool (Human Serum from human male AB plasma, Sigma Aldrich H4522-100ML, Batch 166 #SLCD1948, serum was pooled prior to August 2019). Human MERS-convalescent serum and 167 SARS-CoV-2 convalescent plasma (NIBSC code 20/130) were obtained from the National 168 Institute of Biological Standards and Control, UK.

169

### 170 Calculation of thresholds

171 The threshold for each step 1 plate was defined as the average of the negative controls plus 172 3 standards deviations of the negative controls as described previously (1). The average and 173 median threshold for all step 1 plates was 0.161 AU and 0.166 AU, respectively. Initially, the 174 threshold for the step 2 plate was calculated in the same manner as step 1. However, the threshold calculated with only three negative controls was below the recommended range 175 176 (0.15-0.2 AU at 492 nm). Therefore, another threshold, calculated as 4-times the average blank, which has been demonstrated to be valid for identifying anti-SARS-CoV-2 antibody-177 178 positive samples was used instead (6). Average and median threshold for all step 2 plates 179 were 0.196 AU and 0.1868 AU, respectively.

180

### 181 Calculation of predictivity values

182 The positive predictivity value (PPV) describes the likelihood that a sample which tests 183 positive is a true positive. The negative predictivity value (NPV) describes the likelihood that

184 a sample which tests negative is a true negative (7). Estimated predictivity values were

185 calculated using the following equations:

186

187 *positive predictivity value* 

188 
$$= \frac{\text{sensitivity} \times \text{prevalence}}{(\text{sensitivity} \times \text{prevalence}) + (1 - \text{specificity})(1 - \text{prevalence})}$$

189

190

negative predictivity value

191 
$$= \frac{specificity \times (1 - prevalence)}{[(1 - sensitivity) \times prevalence] + [specificity \times (1 - prevalence)]}$$

192

## 193 Website-based platform for test application and anonymous results reporting

194 Test results were disseminated using a custom web application developed by the OIST IT 195 section and deployed through Microsoft Azure cloud. The front page (Supplementary Figure 196 1B) contained a disclaimer, an instructional video (Supplementary Information), a printable 197 instruction sheet, and other basic information for participants.

The QR code printed and included in each blood sample collection kit was encoded with a unique web URL corresponding to the sample ID of the sticker placed on the sample tube (Supplementary Figure 1A). The stickers and QR codes were created with the mailing feature in Microsoft Office 365 Excel. Following a simple user flow (Supplementary Figure 2), participants could check their test results anonymously either by scanning the QR code with a smartphone or by entering the 6-digit sample ID matching the linear tube barcode.

204 Upon inputting a valid sample ID, participants were prompted to accept a disclaimer 205 before viewing results. After accepting the disclaimer, participants were able to retrieve the 206 status of their sample, including guidance on interpreting test results. Optional information 207 about gender, prior symptoms, age, travel history could be entered voluntarily. This metadata 208 collected anonymously through the SurveyMonkey was а survey on 209 (https://www.surveymonkey.com) platform and linked to the sample ID which was passed as 210 a hidden field via the participant's web browser. Each sample ID was stored in a database 211 table along with values representing test results and disclaimer acceptance. The web 212 application queried this database to retrieve the status of the requested sample ID. The 213 sample IDs were composed of six characters generated randomly from the set of

214 alphanumeric (a-zA-Z0-9) (random characters string generator https://www.random.org/strings/), excluding letters O, I, I, Z, Q and numbers 0, 1, 2, 9 to 215 minimize human read errors. Out of approximately 10<sup>10</sup> combinations, 1000 unique IDs were 216 217 randomly selected. Some additional security features, such as request rate limiting, were implemented to restrict the use of automated tools to retrieve results for all possible sample 218 IDs. Basic functions were developed to allow batch import and export of test results in a 219 220 delimited text format, allowing easy transfer of data between the testing system and the web 221 application database.

222

### 223 Sequence alignments

The full-length sequences of SARS-CoV, MERS-CoV S protein (UniProt ID: P59594 and K9N5Q8,
respectively) were aligned pairwise using ClustalW2 (8), against the S∆cs sequence (3)
(Supplementary Figure 3).

227

### 228 Figure preparation and digital processing

Images of protein gel and Western blot in Figure 1A were acquired by smartphone camera, cropped and adjusted for intensity level in Adobe Photoshop 2020 (Adobe Inc, USA). Original unaltered gel images are available as supplementary files. Original uncropped digital electron micrographs used for Figure 1B and 1C are available as supplementary files. Graphs in Figures 2-5 were plotted with GraphPad Prism v8.4.3 (GraphPad Software, USA), using the scatter plot function (Figure 2).

235

- 236 Results
- 237

### 238 Protein preparation and validation

SARS-CoV-2 trimeric spike and its receptor-binding domain (RBD) were expressed in
 mammalian cells and purified. The quality was verified by Western blot and electron
 microscopy (Figure 1 A-C). We performed single particle cryo-EM and 2D-image classification.
 This confirmed that the trimeric spike protein was properly folded and assembled (Figure 1D).



244

245 Figure 1. A. SDS-PAGE of expressed and purified RBD and spike proteins. Lane: 1, 246 molecular weight marker; 2, cell lysate of expressed RBD; 3, purified RBD; 4, cell lysate of expressed SARS-CoV-2 S; 5, purified spike; 6 and 7, Western blot of purified RBD 247 248 and spike, respectively. **B** and **C**. Electron micrographs of negatively stained purified 249 RBD and spike protein, respectively. D. 2D class averages from boxed aligned single-250 particle cryo-EM images of the trimeric spike protein, showing secondary structure elements indicative of proper folding. Box size 28 nm. Scale bars 20 nm 100 nm in B 251 252 and C, respectively. Original images are available as supplementary data files.

253

### 254 Validation of micro blood sampling method.

Serum samples are typically separated from intravenously collected blood. To confirm that the finger-prick method neither causes unforeseen complications nor affects assay sensitivity, blood samples from two confirmed SARS-CoV-2 PCR-positive individuals were taken both intravenously and by finger-prick on the same day. Although these samples were collected at least 92 days post exposure, they retained a high antibody titer comparable to positive controls, which were collected 10-30 days post onset of symptoms.

The MiniCollect<sup>®</sup> capillary blood collection tube contains a prefilled volume of a polymer gel with a lithium heparin coagulant, which induces blood clotting and can separate the blood clot from serum by centrifugation. Separated serum from four samples were tested in a dilution series in duplicate on both an RBD-coated ELISA plate and a trimeric spike-coated ELISA plate according to the "step 2" ELISA protocol (1) (see Methods and modified plate

All rights reserved. No reuse allowed without permission.

266 layout in Supplementary Figure 1C). For both individuals, titers of intravenous and capillary

267 blood were similar on both the RBD-coated and the spike-coated plate (Figure 2).

268



270

Figure 2: Serum antibody titers from intravenously collected blood and capillary 271 272 blood obtained by finger prick are equivalent. Individuals A and B provided blood 273 samples both intravenously and also by micro-blood collection at least 90 days post exposure. Their endpoint titers were comparable to the positive controls. Each sample 274 275 was tested in duplicate on the same ELISA plate, either coated with SARS-CoV-2 spike RBD (left) or with SARS-CoV-2 trimeric spike protein (right). Each replicate is plotted. 276 Line connects average values. Positive control was pooled serum collected from two 277 278 SARS-CoV-2 PCR-positive individuals 10-30 days after onset of symptoms. Negative 279 controls were collected from individuals prior to November 2019.

280

281 Serological Survey

Overall, 675 sample tubes were collected and processed. Among all the samples received,
zero samples showed signal above threshold in both the RBD screening plate and the spike
confirmatory plate.

All rights reserved. No reuse allowed without permission.

Samples were typically collected, serum separated, and heat-inactivated at the end of each day. Nonetheless, most blood samples can be stored at room temperature in the serum separation tube for several days, in some cases with larger blood volume for up to 1 week. Longer than 1 week is not recommended because the blood begins to dry up. Antibody titers after serum separation have been reported as stable for up to 6 weeks when stored at 4 °C (9). Some participants had difficulty collecting their blood by themselves. In such cases, we encouraged participants to visit the nurses in our institute's Health Center for assistance.

The results for RBD ELISA step 1 are summarized in Figure 3A. Intensities were scaled with respect to the threshold for each plate. Results were compared with multiple negative controls and a collection of serum samples from SARS-CoV-2 PCR positive individuals. A subset of 63 OIST samples had serum antibody reactivity above the established threshold, and only a few were at the same level as the PCR-positive individuals. Titers from all PCR-positive individuals were above the threshold. Samples from all PCR-positive individuals were taken by capillary blood collection at least one month post onset of symptoms.

299 Results for the final ELISA step 2 are shown in Figure 3B and 3C. Of the 63 OIST samples 300 that were positive in RBD step 1, all had serum antibody reactivity below threshold for all 5 301 dilutions when tested against the SARS-CoV-2 trimeric spike protein in step 2, indicating a 302 9.9% false positive rate in the highly sensitive step 1. Antibody titers (Figure 3C) of serum 303 samples from all PCR positive individuals were above the threshold for at least two dilutions. 304 Results were classified as "positive" (above threshold), "negative" (below threshold), or 305 "undetermined". All RBD-positive OIST samples were below threshold in the anti-spike ELISA 306 (Figure 3B and 3C). The most common cause of an undetermined result was the failure to 307 provide sufficient serum. This was the case for 40 of the 675 samples that we received. If the 308 result was undetermined, the participant was encouraged to pick up another kit and try again.

309 From the SurveyMonkey platform, 206 completed surveys were received, or 31 % of 310 all samples collected. The collective results showed that 17 % of the survey takers believed 311 that they had experienced some COVID-19 symptoms in the past 6 months and 31 % had 312 travelled outside of Okinawa in the past 6 months. The age distribution was as follows: 20-40 313 years old, 60 %; 40-60 years, 36 %; greater than 60 years, 4 %. The gender distribution was 314 roughly equal.

315





Figure 3: Summary of OIST Serological Survey. A. In assay step 1 (anti-RBD ELISA), 63 317 318 OIST samples were above the threshold (3 standard deviations above the average 319 negative control). B. All positives from step 1 were tested in step 2 (anti-spike ELISA). 320 No OIST samples were above the threshold (4 times the average background). C. Step-321 2 titers were measured at dilutions 1:100, 1:300, 1:900, 1:2700, and 1:8100. Positive controls showed much stronger signal than the OIST samples even at high dilution. 322 The dotted line indicates the respective threshold level. All negative controls are 323 samples taken from patients prior to November 2019. Sera from PCR positive 324 individuals were collected at least 10-30 days post onset of symptoms. 325

326

316

#### 327 Assay Specificity

328 The specificity of the Mount Sinai Hospital Clinical Laboratory COVID-19 ELISA Antibody Test has been reported as 100 % for 74 negative control samples (10) and the developers 329 330 demonstrated no cross-reactivity against the common coronavirus strain NL63 (3). Of note, 331 as part of the protocol establishing process, we used a SARS-CoV-2 convalescent plasma 332 (NIBSC code 20/130) and human MERS-convalescent serum to confirm the specificity of the 333 assay in both steps. As expected, SARS-CoV-2 convalescent plasma showed strong reactivity 334 in both plates. MERS-convalescent serum, on the other hand, was negative in anti-RBD cross-335 reactivity, but positive in anti-spike cross-reactivity (Figure 4).

336

To understand the basis of the MERS-convalescent serum cross-reactivity, we performed an amino acid sequence alignment of SARS-CoV-2 spike and MERS-CoV spike protein. Sequence alignment demonstrated that the SARS-CoV-2 RBD shares 18.7 % identity with MERS-CoV RBD, but alignment of the full-length spike sequence demonstrated higher 32.3 % sequence identity between SARS-CoV-2, and MERS-CoV (Supplementary Figure 3).





343

Figure 4: Titers of SARS-CoV-2 and MERS-CoV convalescent serum in RBD and spike ELISA. Each sample was tested in duplicate on the same plate. Line connects average values. Positive control is pooled serum from two CoV-2 PCR positive individuals 10-30 days after onset of symptoms. Negative control is from a commercial serum pool.

348

# 349 Longevity of Antibody Titers

We obtained multiple samples from two PCR-confirmed SARS-CoV2 positive individuals over an extended period of time and analyzed their serum antibody titers against the spike protein by ELISA. Individual 2 has a known exposure date, because the person was part of a documented cluster infection. Antibody titer was measured by anti-spike ELISA in a series of dilutions (Figure 5) in quadruplicate. Anti-spike antibodies titer remained above threshold 6.5 months post exposure.







Figure 5: Resiliency of anti-spike antibody titer over time. Serum samples from two recovered COVID-19 patients were collected at 52 and 87 days post onset of symptoms (Individual 1, left) or at 78, 92, 169, and 197 days post exposure to the COVID-19 virus (Individual 2, right). Anti-spike antibody titers were measured by ELISA at 50, 150, 450, 1350, and 4050 times dilution in quadruplicate. The average and standard deviation for each dilution of each sample is plotted, revealing detectable antibody titers at 1:450 dilution for up to 6.5 months post exposure.

365

### 366 Discussion

367

### 368 Micro blood sampling is a good alternative to venous blood collection

369 Micro blood sampling by finger prick at home avoids unnecessary risk and effort by healthcare 370 workers and allows parallel collection of large numbers of samples within a short period of 371 time. The combination of patient-driven sample self-collection with a standardized highly 372 specific and selective ELISA in a centralized lab improves the reliability of results while keeping 373 costs low. Serum can be separated from whole blood up to 1 week after collection. Provided that temperatures are kept close to ambient temperature, this would allow for shipping of 374 375 samples from collection site to the testing site by mail. The main bottleneck is serum transfer from collection tube to ELISA plate. This step may be accelerated with a sophisticated 376 integrated liquid handling system. We showed that antibody titers from capillary blood serum 377 378 are equivalent to titers measured from venous blood (Figure 2). The Infectious Diseases 379 Society of America Guidelines on the Diagnosis of COVID-19 currently make no 380 recommendations for or against the use of capillary blood in serological assays due to a

knowledge gap on the subject (11). We hope that the success of our study begins to fill this knowledge gap, paving the way for further proof-of-concept studies using capillary blood. Our survey revealed that micro blood sampling of capillary blood is a practical, cost-efficient method using as little as one drop of blood (approximately 30 μL) per sample. Such a small sample volume would even allow testing of newborns using neonatal heel prick.

386

### 387 Anonymization and web-based reporting

The web-based platform served as an efficient means to conduct this study anonymously while providing instructions and communicating results to participants. Anonymization was achieved by randomly barcoded samples without the need to enter personal data. From the 1,154 staff and students at OIST (as of May 2020), 675 samples were received, of which only 41 samples (6.1%) could not be tested due to lack of serum or improper sample collection. The success of our practical web-based method indicates that this method may be used for larger epidemiological studies.

395

### 396 Significance of OIST results

The serological survey of students and employees carried out at OIST on Okinawa, Japan, in August 2020 revealed no seroconversion among this small population. The test has reliably identified all previously confirmed PCR-positive individuals and controls, with reactivities as high as 7 times threshold. Our results assert strong confidence in this 2-step assay, which has received FDA-emergency approval (2).

402 Okinawa has, thus far, enjoyed moderately low numbers of COVID-19 cases among its 403 population. Other recent serological surveys in Japan, have found seroprevalence as low as 404 0.43 % (among 44,066 employees and business partners of the company Softbank and healthcare workers across Japan) (12), 0.1 % (1,971 citizens of Tokyo), 0.03 % (3,009 citizens 405 406 in Miyagi Prefecture) and 0.17 % (2,970 citizens of Osaka prefecture) (13). At such low seroprevalence, high assay specificity is critical to achieving a high predictive value (14, 15). 407 408 Although accurate estimation of the actual seroprevalence among OIST staff and students 409 (including the 45 % of employees that did not participate in the survey) is not possible, 410 assuming a seroprevalence between 0.03 % (Tokyo) and 0.43 % (Softbank), with a known 411 assay specificity of close to 100 % and a sensitivity of 92.5 % for the Mt. Sinai Antibody Test

412 used here (*10*), we estimate the negative predictivity value of our assay to be greater than413 99.9%.

414

### 415 Longevity of antibody titers

Analysis of serum antibody titers against SARS-CoV2 spike protein taken at multiple time points from two PCR-positive individuals post onset of symptoms (or post verified exposure) revealed only moderate decrease over time, with robust antibody titers above threshold persisting for up to 6.5 months (Figure 5). In combination with recent reports of high efficacy of vaccines currently in phase-3 trials, our results add to the growing amount of evidence that spike-based vaccines may be able to elicit longer-lasting immunity.

422

### 423 Cross-reactivity of MERS convalescent serum with SARS-CoV-2 spike protein

424 SARS-CoV, SARS-CoV-2 and other human coronaviruses such as NL63 use aceE2 as 425 receptor (16, 17) mediated by the class-1 fusion protein S before entry through the plasma 426 membrane, or via a clathrin-dependent endosomal pathway (18). MERS-CoV utilizes a similar 427 mechanism but uses the dipeptidyl peptidase 4 receptor (dpp4) instead (19). Dpp4 does not 428 share sequence and structural similarity to previously identified human coronavirus receptors 429 such as ACE2 or APN (16, 17, 20). Convalescent plasma samples from SARS-CoV-infected 430 patients have moderate cross-reactivity with SARS-CoV-2 spike protein, but no cross-431 neutralization (21). The assay used here has been shown to have no cross-reactivity with the 432 seasonal human coronavirus NL63 (3). Interestingly, when we tested human convalescent 433 serum from MERS patients with our ELISA, we found explicit cross-reactivity between MERS 434 serum and SARS-CoV-2 spike with an antibody titer similar to that of SARS-CoV-2 plasma. Our 435 sequence alignment indicated only 18.7 % sequence identity between SARS-CoV-2 RBD and 436 MERS-CoV RBD. On the other hand, we found 32.3 % identity between SARS-CoV-2 and MERS-437 CoV spike (S) (Supplementary Figure 3), indicating higher sequence conservation in the other 438 domains of the spike protein, thus providing a possible explanation for the observed cross-439 reactivity. For a given SARS-CoV-2 convalescent serum sample with an anti-spike titer of 440 >1:1350, the probability of viral neutralization at the FDA-recommended level for 441 convalescent plasma used for COVID-19 treatment (viral neutralization titer ≥1:160), has been 442 found to be  $\geq$ 80 % (22). Our data shows strong MERS cross-reactivity with SARS-CoV-2 spike 443 at titers close to 1:1350. Although most effective neutralizing antibodies against

All rights reserved. No reuse allowed without permission.

coronaviruses target the RBD, neutralizing antibodies against SARS-CoV-2 S1-N-terminal

444

473

domain (23) and SARS-CoV S2 domain (24) have also been identified. Our data suggests that 445 446 MERS convalescent serum may also contain such neutralizing antibodies against SARS-CoV-2. 447 448 **Author contributions** 449 450 M.M., ELISA implementation, validation, analysis. M.M., S.S., N.S., ELISA execution. S.S., test 451 kit development. T.K., N.S., protein expression. T.K., protein purification. T.K., J.H., electron 452 microscopy and image analysis. C.B., workflow automation. K.K., sequence alignment. T.R., 453 S.J., website design, sample codes. M.N. provided finger-prick validation samples, controls, 454 and collected long-term samples. T.M., medical advice and study ethics. M.C., mentoring and 455 advice, website content, study ethics. M.W. project creation and supervision. M.M., M.W. 456 wrote initial draft. All authors edited and contributed to the final manuscript. 457 458 **Competing interests** 459 460 The authors declare no competing interests. 461 462 Ethics, consent, and permissions 463 The experiments were conducted according to a proposal approved by the OIST Human 464 Subjects Research Review Committee (Protocol Title: "Survey of antibody retention rate for 465 OIST staff and students against SARS-CoV-2"; application reference number: HSR-2020-026). 466 467 All methods, including obtaining informed consent, were conducted in accordance with the Declaration of Helsinki and other relevant guidelines including the Ethical Guidelines for 468 469 Medical and Health Research Involving Human Subjects set forth by the Japanese government. Consent to publish the accumulated anonymized data has been obtained from all participants 470 of the study upon enrollment. The protocol for the positive control samples has been 471 approved by the Institutional Review Board (IRB) of Okinawa Chubu Hospital with the 472

474 reference number HSR-2020-16-2 approved by the OIST Human Subjects Research Review

confirmation number 2020-23. This protocol is furthermore included in the application with

All rights reserved. No reuse allowed without permission.

475 Committee (Protocol Title: "Establishment of new serological diagnostic test by ELISA to grasp
476 the post-infection population with novel coronavirus in Okinawa").

477

#### 478 Data availability

479

480 Original uncropped unscaled images for Figures 1 A-D are available as supplementary files.
481 Requests for further information or raw data should be directed to the corresponding author.

482

### 483 Acknowledgements

484

485 MERS-CoV convalescent sera was kindly provided by Dr Giada Mattiuzzo (NIBSC, United 486 Kingdom), in collaboration with Dr Manki Song (International Vaccine Institute, South Korea) Chungnam National University Hospital, and funded by Coalition for Epidemic Preparedness 487 488 Innovations (CEPI, Norway). We thank Kieran Deasy and Mouez Lassoued for 3D-printing tube 489 racks. We are grateful to Mahesh Bandi for advice on statistics and to Alejandro Villar Brillones 490 for advice on automation. We thank Chris Wu for developing the website's theme and 491 stylesheets. We thank Pinaki Chakraborty for providing the time and expertise of his technician C.B. This work was supported by the Platform Project for Supporting Drug 492 493 Discovery and Life Science Research (BINDS) from AMED, under grant number 494 JP18am0101076 (to M.W.). We acknowledge financial support by OPG for a larger serological study, as well as direct funding from OIST. 495

496

### 497 References

- 498
- D. Stadlbauer *et al.*, SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a
   Serological Assay, Antigen Production, and Test Setup. *Curr. Protoc. Microbiol.* 57
- 501 (2020), doi:10.1002/cpmc.100.
- 502 2. "Accelerated emergency use authorization (EUA) summary COVID-19 ELISA IGG
   503 antibody test (Mount Sinai Laboratory)" (2020), (available at

504 https://www.fda.gov/media/137029/download).

505 3. F. Amanat *et al.*, A serological assay to detect SARS-CoV-2 seroconversion in humans.
506 *Nat. Med.* 26, 1033–1036 (2020).

507	4.	S. Q. Zheng et al., MotionCor2: anisotropic correction of beam-induced motion for
508		improved cryo-electron microscopy. Nat. Methods. 14, 331–332 (2017).
509	5.	J. Zivanov et al., New tools for automated high-resolution cryo-EM structure
510		determination in RELION-3. Elife. 7 (2018), doi:10.7554/eLife.42166.
511	6.	S. Pickering et al., Comparative assessment of multiple COVID-19 serological
512		technologies supports continued evaluation of point-of-care lateral flow assays in
513		hospital and community healthcare settings. PLOS Pathog. 16, e1008817 (2020).
514	7.	D. G. Altman, j. M. Bland, Statistics Notes: Diagnostic tests 2: Predictive values. BMJ.
515		<b>309</b> , 102 (1994).
516	8.	M. A. Larkin et al., Clustal W and Clustal X version 2.0. Bioinformatics. 23, 2947–2948
517		(2007).
518	9.	D. Stadlbauer et al., Anti-SARS-CoV -2 Spike Antibodies are Stable in Convalescent
519		Plasma when Stored at 4° Celsius for at Least 6 Weeks . Transfusion (2020),
520		doi:10.1111/trf.16047.
521	10.	A. Wajnberg et al., medRxiv, in press, doi:10.1101/2020.07.14.20151126.
522	11.	K. E. Hanson et al., Infectious Diseases Society of America Guidelines on the Diagnosis
523		of COVID-19:Serologic Testing. Clin. Infect. Dis. (2020), doi:10.1093/cid/ciaa1343.
524	12.	"Softbank Group Antibody Test Results" (2020), (available at
525		https://group.softbank/system/files/pdf/antibodytest.pdf).
526	13.	"Tokyo Osaka and Miyagi Prefecture Antibody Possession Survey Results" (2020),
527		(available at https://www.mhlw.go.jp/content/10906000/000640184.pdf).
528	14.	J. D. Whitman et al., Evaluation of SARS-CoV-2 serology assays reveals a range of test
529		performance. Nat. Biotechnol. <b>38</b> , 1174–1183 (2020).
530	15.	N. C. Brownstein, Y. A. Chen, medRxiv Prepr. Serv. Heal. Sci., in press,
531		doi:10.1101/2020.06.04.20122358.
532	16.	W. Li et al., Angiotensin-converting enzyme 2 is a functional receptor for the SARS
533		coronavirus. <i>Nature</i> . <b>426</b> , 450–454 (2003).
534	17.	F. Li, W. Li, M. Farzan, S. C. Harrison, Structural biology: Structure of SARS coronavirus
535		spike receptor-binding domain complexed with receptor. Science (80 ). 309, 1864–
536		1868 (2005).
537	18.	T. Tang, M. Bidon, J. A. Jaimes, G. R. Whittaker, S. Daniel, Coronavirus membrane
538		fusion mechanism offers a potential target for antiviral development. Antiviral Res.

539		<b>178</b> (2020), , doi:10.1016/j.antiviral.2020.104792.
540	19.	V. S. Raj et al., Dipeptidyl peptidase 4 is a functional receptor for the emerging human
541		coronavirus-EMC. <i>Nature</i> . <b>495</b> , 251–254 (2013).
542	20.	N. Wang et al., Structure of MERS-CoV spike receptor-binding domain complexed
543		with human receptor DPP4. Cell Res. 23, 986–993 (2013).
544	21.	H. Lv et al., Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV
545		Infections. <i>Cell Rep.</i> <b>31</b> (2020), doi:10.1016/j.celrep.2020.107725.
546	22.	E. Salazar et al., Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and
547		receptor binding domain IgG correlate with virus neutralization. J. Clin. Invest. (2020),
548		doi:10.1172/jci141206.
549	23.	X. Chi et al., A neutralizing human antibody binds to the N-terminal domain of the
550		Spike protein of SARS-CoV-2. Science (80 ). <b>369</b> , 650–655 (2020).
551	24.	J. Duan et al., A human SARS-CoV neutralizing antibody against epitope on S2 protein.
552		Biochem. Biophys. Res. Commun. <b>333</b> , 186–193 (2005).
553		